![Page 1: Current Controversies in Dyslipidemia Management:](https://reader036.vdocuments.net/reader036/viewer/2022081515/58ecde6f1a28ab4d4b8b4603/html5/thumbnails/1.jpg)
LDL Cholesterol : How Low Should You Go?
Magdy El-MasryProf. of CardiologyTanta University
Current Controversies in Dyslipidemia Management: A Point-Counterpoint Discussion
![Page 2: Current Controversies in Dyslipidemia Management:](https://reader036.vdocuments.net/reader036/viewer/2022081515/58ecde6f1a28ab4d4b8b4603/html5/thumbnails/2.jpg)
FraminghamMRFIT
LRC-CPPTCoronary Drug
ProjectHelsinki HeartCLAS (angio)
Angiographic Trials (FATS, POSCH, SCOR, STARS, Ornish, MARS)Meta-Analyses
(Holme, Rossouw)
4S, WOSCOPS, CARE, LIPID,
AFCAPS/TexCAPS, VAHIT, others
1970s
NCEPATP IGuidelines1988
NCEPATP II
Guidelines1993
NCEPATP III
Guidelines2002
ATP III UPDATE
2004
HPS, PROVE-IT, ASCOT, ALLHAT, PROSPER
National Cholesterol Education ProgramAdult Treatment Panel
![Page 4: Current Controversies in Dyslipidemia Management:](https://reader036.vdocuments.net/reader036/viewer/2022081515/58ecde6f1a28ab4d4b8b4603/html5/thumbnails/4.jpg)
![Page 5: Current Controversies in Dyslipidemia Management:](https://reader036.vdocuments.net/reader036/viewer/2022081515/58ecde6f1a28ab4d4b8b4603/html5/thumbnails/5.jpg)
LDL-C Goals (ATP-III)Risk category Goal LDL (mg/dl) CAD & CAD risk equivalent <100 high risk
<70 optional
2 or more major risk factors + 10 yr risk >20%
<100 high risk <70 optional
2 or more major risk factors +10 yr risk 10-20%
<130 moderately high risk <100 optional
2 or more major risk factors +10 yr risk <10%
0-1 major risk factor
<130 moderate risk
<160 low risk
![Page 6: Current Controversies in Dyslipidemia Management:](https://reader036.vdocuments.net/reader036/viewer/2022081515/58ecde6f1a28ab4d4b8b4603/html5/thumbnails/6.jpg)
Keep it Simple : Start the Statin or Not ?
![Page 7: Current Controversies in Dyslipidemia Management:](https://reader036.vdocuments.net/reader036/viewer/2022081515/58ecde6f1a28ab4d4b8b4603/html5/thumbnails/7.jpg)
To Statin or Not to Statin?
Statins for everyone?
Put statins in the drinking water?
![Page 8: Current Controversies in Dyslipidemia Management:](https://reader036.vdocuments.net/reader036/viewer/2022081515/58ecde6f1a28ab4d4b8b4603/html5/thumbnails/8.jpg)
Identified 4 statin benefit groups ----- Focus efforts to reduce ASCVD events
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol toReduce Atherosclerotic Cardiovascular Risk in Adults
![Page 9: Current Controversies in Dyslipidemia Management:](https://reader036.vdocuments.net/reader036/viewer/2022081515/58ecde6f1a28ab4d4b8b4603/html5/thumbnails/9.jpg)
Secondary Prevention
Primary prevention
![Page 10: Current Controversies in Dyslipidemia Management:](https://reader036.vdocuments.net/reader036/viewer/2022081515/58ecde6f1a28ab4d4b8b4603/html5/thumbnails/10.jpg)
![Page 11: Current Controversies in Dyslipidemia Management:](https://reader036.vdocuments.net/reader036/viewer/2022081515/58ecde6f1a28ab4d4b8b4603/html5/thumbnails/11.jpg)
![Page 12: Current Controversies in Dyslipidemia Management:](https://reader036.vdocuments.net/reader036/viewer/2022081515/58ecde6f1a28ab4d4b8b4603/html5/thumbnails/12.jpg)
http://clincalc.com/Cardiology/ASCVD/PooledCohort.aspx
This is the new equation
![Page 13: Current Controversies in Dyslipidemia Management:](https://reader036.vdocuments.net/reader036/viewer/2022081515/58ecde6f1a28ab4d4b8b4603/html5/thumbnails/13.jpg)
![Page 14: Current Controversies in Dyslipidemia Management:](https://reader036.vdocuments.net/reader036/viewer/2022081515/58ecde6f1a28ab4d4b8b4603/html5/thumbnails/14.jpg)
Statin DoseBenefit Group
The guideline identifies high- and
moderate-intensity statin
therapy for use in primary and secondary prevention
![Page 15: Current Controversies in Dyslipidemia Management:](https://reader036.vdocuments.net/reader036/viewer/2022081515/58ecde6f1a28ab4d4b8b4603/html5/thumbnails/15.jpg)
Non-statin therapies
• For hyperlipidemia, non statin therapies, alone or in combination with statins, do not provide acceptable risk reduction benefits compared to adverse effects.
• These include:–Ezetimibe–Fibrates–Fish oil–Niacin
• For the most part, these should be avoided with few exceptions
![Page 16: Current Controversies in Dyslipidemia Management:](https://reader036.vdocuments.net/reader036/viewer/2022081515/58ecde6f1a28ab4d4b8b4603/html5/thumbnails/16.jpg)
What has changed compared to ATP-III guideline?
• Initiate either moderate-intensity or high-intensity statin therapy for patients who fall into the four categories
• Unlike ATP-III, Do not titrate to a specific LDL cholesterol target
• Measure lipids during follow-up to assess adherence to treatment, not to achieve a specific LDL target
![Page 17: Current Controversies in Dyslipidemia Management:](https://reader036.vdocuments.net/reader036/viewer/2022081515/58ecde6f1a28ab4d4b8b4603/html5/thumbnails/17.jpg)
Evidence to support controversy in 2013 ACC/AHA Guideline
![Page 18: Current Controversies in Dyslipidemia Management:](https://reader036.vdocuments.net/reader036/viewer/2022081515/58ecde6f1a28ab4d4b8b4603/html5/thumbnails/18.jpg)
Recommendations for statin and combination treatment in people with diabetes
*In addition to lifestyle therapy.
**ASCVD risk factors include LDL- C ≥100 mg/dL, high BP, smoking, CKD, albuminuria, and family history of premature ASCVD.
2017ADA
![Page 19: Current Controversies in Dyslipidemia Management:](https://reader036.vdocuments.net/reader036/viewer/2022081515/58ecde6f1a28ab4d4b8b4603/html5/thumbnails/19.jpg)
2 Studies Support Guidelines for Wider Use of Statins
![Page 20: Current Controversies in Dyslipidemia Management:](https://reader036.vdocuments.net/reader036/viewer/2022081515/58ecde6f1a28ab4d4b8b4603/html5/thumbnails/20.jpg)
2016
![Page 21: Current Controversies in Dyslipidemia Management:](https://reader036.vdocuments.net/reader036/viewer/2022081515/58ecde6f1a28ab4d4b8b4603/html5/thumbnails/21.jpg)
Does HOPE-3 give hope?
This finding was independent of the cholesterol levels when patient started the trial. You “set it and forget it”
Importantly, the results show the benefits of using statins based on risk factors for disease, rather than the traditional approach of looking at lipid levels to guide decisions.
Statins reduce the risk of cardiovascular disease in intermediate risk patients
![Page 22: Current Controversies in Dyslipidemia Management:](https://reader036.vdocuments.net/reader036/viewer/2022081515/58ecde6f1a28ab4d4b8b4603/html5/thumbnails/22.jpg)
Four Major Statin Benefit Groups
![Page 23: Current Controversies in Dyslipidemia Management:](https://reader036.vdocuments.net/reader036/viewer/2022081515/58ecde6f1a28ab4d4b8b4603/html5/thumbnails/23.jpg)
Case 1
50 year old white female• Total cholesterol 180• HDL: 50• SBP: 130• taking anti-hTN meds• +diabetic• +smoker• Calculated 10 yr ASCVD: 9.8%
![Page 24: Current Controversies in Dyslipidemia Management:](https://reader036.vdocuments.net/reader036/viewer/2022081515/58ecde6f1a28ab4d4b8b4603/html5/thumbnails/24.jpg)
![Page 25: Current Controversies in Dyslipidemia Management:](https://reader036.vdocuments.net/reader036/viewer/2022081515/58ecde6f1a28ab4d4b8b4603/html5/thumbnails/25.jpg)
Dosing Statins
![Page 26: Current Controversies in Dyslipidemia Management:](https://reader036.vdocuments.net/reader036/viewer/2022081515/58ecde6f1a28ab4d4b8b4603/html5/thumbnails/26.jpg)
Case 2
22 yo white male• LDL: 195• SBP: 120• Not taking anti-HTN meds• Non-diabetic• Non-smoker
![Page 27: Current Controversies in Dyslipidemia Management:](https://reader036.vdocuments.net/reader036/viewer/2022081515/58ecde6f1a28ab4d4b8b4603/html5/thumbnails/27.jpg)
![Page 28: Current Controversies in Dyslipidemia Management:](https://reader036.vdocuments.net/reader036/viewer/2022081515/58ecde6f1a28ab4d4b8b4603/html5/thumbnails/28.jpg)
Dosing Statins
![Page 29: Current Controversies in Dyslipidemia Management:](https://reader036.vdocuments.net/reader036/viewer/2022081515/58ecde6f1a28ab4d4b8b4603/html5/thumbnails/29.jpg)
Case 3
62 year old AA male • Total cholesterol: 140• Low HDL: 35• SBP: 130 mmHg• Not taking anti-hypertensive medications• Non-diabetic• Non-smoker• Calculated 10 yr risk of ASCVD : 9.1%
![Page 30: Current Controversies in Dyslipidemia Management:](https://reader036.vdocuments.net/reader036/viewer/2022081515/58ecde6f1a28ab4d4b8b4603/html5/thumbnails/30.jpg)
![Page 31: Current Controversies in Dyslipidemia Management:](https://reader036.vdocuments.net/reader036/viewer/2022081515/58ecde6f1a28ab4d4b8b4603/html5/thumbnails/31.jpg)
Dosing Statins
![Page 32: Current Controversies in Dyslipidemia Management:](https://reader036.vdocuments.net/reader036/viewer/2022081515/58ecde6f1a28ab4d4b8b4603/html5/thumbnails/32.jpg)
Case 4
48 yo white female• Total cholesterol 180• HDL: 55• SBP: 130• Not taking anti-hTN meds• +diabetic• Non-smoker• Calculated 10 yr risk ASCVD : 1.8%
![Page 33: Current Controversies in Dyslipidemia Management:](https://reader036.vdocuments.net/reader036/viewer/2022081515/58ecde6f1a28ab4d4b8b4603/html5/thumbnails/33.jpg)
![Page 34: Current Controversies in Dyslipidemia Management:](https://reader036.vdocuments.net/reader036/viewer/2022081515/58ecde6f1a28ab4d4b8b4603/html5/thumbnails/34.jpg)
Dosing Statins
![Page 35: Current Controversies in Dyslipidemia Management:](https://reader036.vdocuments.net/reader036/viewer/2022081515/58ecde6f1a28ab4d4b8b4603/html5/thumbnails/35.jpg)
Case 5
66 yo white female • High Total cholesterol: 230• HDL: 55• SBP: 150• taking anti-HTN meds• Non-diabetic• Non-smoker• Calculated 10 yr risk of ASCVD : 2.0 %
![Page 36: Current Controversies in Dyslipidemia Management:](https://reader036.vdocuments.net/reader036/viewer/2022081515/58ecde6f1a28ab4d4b8b4603/html5/thumbnails/36.jpg)
![Page 37: Current Controversies in Dyslipidemia Management:](https://reader036.vdocuments.net/reader036/viewer/2022081515/58ecde6f1a28ab4d4b8b4603/html5/thumbnails/37.jpg)
What’s changed ? Yet another new ESC lipid guidelines
![Page 38: Current Controversies in Dyslipidemia Management:](https://reader036.vdocuments.net/reader036/viewer/2022081515/58ecde6f1a28ab4d4b8b4603/html5/thumbnails/38.jpg)
Total Cardiovascular Risk Estimation
CV risk in the context of these guidelines means the likelihood of a person developing a fatal or non-fatal
atherosclerotic CV event over a defined period of time.
Systemic Coronary Risk Estimation (SCORE) System
![Page 39: Current Controversies in Dyslipidemia Management:](https://reader036.vdocuments.net/reader036/viewer/2022081515/58ecde6f1a28ab4d4b8b4603/html5/thumbnails/39.jpg)
SCORE not used for Diabetic patients , Patient with documented CVD or CKD patients
They already Very high risk or High risk
![Page 40: Current Controversies in Dyslipidemia Management:](https://reader036.vdocuments.net/reader036/viewer/2022081515/58ecde6f1a28ab4d4b8b4603/html5/thumbnails/40.jpg)
![Page 41: Current Controversies in Dyslipidemia Management:](https://reader036.vdocuments.net/reader036/viewer/2022081515/58ecde6f1a28ab4d4b8b4603/html5/thumbnails/41.jpg)
4 Risk categories
![Page 42: Current Controversies in Dyslipidemia Management:](https://reader036.vdocuments.net/reader036/viewer/2022081515/58ecde6f1a28ab4d4b8b4603/html5/thumbnails/42.jpg)
I A
IIa A
IIa C
Recommendations for treatment targets for LDL-C
![Page 43: Current Controversies in Dyslipidemia Management:](https://reader036.vdocuments.net/reader036/viewer/2022081515/58ecde6f1a28ab4d4b8b4603/html5/thumbnails/43.jpg)
ESC 2016 Risk Categories & LDL Goal
![Page 44: Current Controversies in Dyslipidemia Management:](https://reader036.vdocuments.net/reader036/viewer/2022081515/58ecde6f1a28ab4d4b8b4603/html5/thumbnails/44.jpg)
Continental Divide on Lipid GuidelinesThe U.S. guidelines recommend giving a statin to all high-risk patients, even those with low cholesterol, but the ESC/EAS guidelines do not do that (no tx if low LDL despite high risk).The American approach would mean considerably more people in Europe being on a statin.
While the ACC/AHA guidelines do not specify a numeric goal, the ESC/EAS guidelines set a target of a reduction in LDL
Fasting is no longer required before screening for lipid levels in Europe due to "new evidence that non-
fasting blood samples give similar results for cholesterol." However, fasting is recommended in
the U.S. the guidelines.
![Page 45: Current Controversies in Dyslipidemia Management:](https://reader036.vdocuments.net/reader036/viewer/2022081515/58ecde6f1a28ab4d4b8b4603/html5/thumbnails/45.jpg)
ESC comes out in favor of LDL targets This raises the question: How will we reach these goals?
If we do not reach our goals with diet alone, we are recommending the prescription of a statin as the first step.
In the few cases where there is true statin intolerance, then the second step would be to use either ezetimibe or a bile acid sequestrant.
If, with a statin at the highest tolerable dose, we do not reach the goal, then we have to think of combinations. Nowadays, we know that by combining ezetimibe
and a statin, we can achieve a better result in terms of cardiovascular disease prevention.
In patients at very high risk, with persistent high LDL-C levels despite treatment with the maximal tolerated statin dose, even in combination with ezetimibe, or in
patients who really are completely statin intolerant, then this new family of drugs, the PCSK9 inhibitors, may be considered.
![Page 46: Current Controversies in Dyslipidemia Management:](https://reader036.vdocuments.net/reader036/viewer/2022081515/58ecde6f1a28ab4d4b8b4603/html5/thumbnails/46.jpg)
Statins inhibit cholesterol synthesis in the liver, ezetimibe blocks cholesterol absorption in the intestine, and PCSK9 inhibitors block the PCSK9-mediated degradation of LDL receptors.
Statins, ezetimibe, and PCSK9 inhibitors all increase the expression of LDL receptors and reduce LDL-cholesterol levels (by percentages shown).
![Page 47: Current Controversies in Dyslipidemia Management:](https://reader036.vdocuments.net/reader036/viewer/2022081515/58ecde6f1a28ab4d4b8b4603/html5/thumbnails/47.jpg)
Ezetimibe and PCSK9 inhibition join the mainstream of lipid‑lowering therapy
LDL-C The debate goes on
![Page 48: Current Controversies in Dyslipidemia Management:](https://reader036.vdocuments.net/reader036/viewer/2022081515/58ecde6f1a28ab4d4b8b4603/html5/thumbnails/48.jpg)
Schematic Depiction of the Statin Hypothesis.The reduction in LDL- C with lipid-modifying agents is plotted against the reduction in cardiovascular events under either the LDL hypothesis or the statin hypothesis. The putative added “pleiotropic” effects of statins (effects that are un-related to their lipid-lowering effects) are represented by the shaded area. The IMPROVE-IT trial provides im-portant new evidence in favor of the LDL hypothesis.
![Page 49: Current Controversies in Dyslipidemia Management:](https://reader036.vdocuments.net/reader036/viewer/2022081515/58ecde6f1a28ab4d4b8b4603/html5/thumbnails/49.jpg)
![Page 50: Current Controversies in Dyslipidemia Management:](https://reader036.vdocuments.net/reader036/viewer/2022081515/58ecde6f1a28ab4d4b8b4603/html5/thumbnails/50.jpg)
IMProved Reduction of Outcomes: Vytorin Efficacy International Trial
A Multicenter, Double-Blind, Randomized Study to Establish the
Clinical Benefit and Safety of Vytorin (Ezetimibe/Simvastatin Tablet) vs Simvastatin Monotherapy in High-
Risk Subjects Presenting With Acute Coronary Syndrome
IMPROVE-IT
![Page 51: Current Controversies in Dyslipidemia Management:](https://reader036.vdocuments.net/reader036/viewer/2022081515/58ecde6f1a28ab4d4b8b4603/html5/thumbnails/51.jpg)
Patients stabilized post ACS ≤ 10 days:LDL-C 50–125*mg/dL (or 50–100**mg/dL if prior lipid-lowering Rx)
Standard Medical & Interventional Therapy
Ezetimibe / Simvastatin 10 / 40 mg
Simvastatin 40 mg
Follow-up Visit Day 30, every 4 months
Duration: Minimum 2 ½-year follow-up (at least 5250 events)
Primary Endpoint: CV death, MI, hospital admission for UA,coronary revascularization (≥ 30 days after randomization), or stroke
N=18,144
Uptitrated to Simva 80 mg if LDL-C > 79(adapted per
FDA label 2011)
Study Design *3.2mM **2.6mM
Cannon CP AHJ 2008;156:826-32; Califf RM NEJM 2009;361:712-7; Blazing MA AHJ 2014;168:205-12
90% power to detect ~9% difference
![Page 52: Current Controversies in Dyslipidemia Management:](https://reader036.vdocuments.net/reader036/viewer/2022081515/58ecde6f1a28ab4d4b8b4603/html5/thumbnails/52.jpg)
Conclusions
IMPROVE-IT: First trial demonstrating incremental clinical benefit when adding a non-statin agent (ezetimibe) to statin therapy:
YES: Non-statin lowering LDL-C with ezetimibereduces cardiovascular events
YES: Even Lower is Even Better(achieved mean LDL-C 53 vs. 70 mg/dL at 1 year)
YES: Confirms ezetimibe safety profile
Reaffirms the LDL hypothesis, that reducing LDL-C prevents cardiovascular events
Results could be considered for future guidelines
![Page 53: Current Controversies in Dyslipidemia Management:](https://reader036.vdocuments.net/reader036/viewer/2022081515/58ecde6f1a28ab4d4b8b4603/html5/thumbnails/53.jpg)
![Page 54: Current Controversies in Dyslipidemia Management:](https://reader036.vdocuments.net/reader036/viewer/2022081515/58ecde6f1a28ab4d4b8b4603/html5/thumbnails/54.jpg)
Proprotein convertase subtilisin/kexin type 9 (PCSK9)
![Page 55: Current Controversies in Dyslipidemia Management:](https://reader036.vdocuments.net/reader036/viewer/2022081515/58ecde6f1a28ab4d4b8b4603/html5/thumbnails/55.jpg)
PCSK9 inhibitors
![Page 56: Current Controversies in Dyslipidemia Management:](https://reader036.vdocuments.net/reader036/viewer/2022081515/58ecde6f1a28ab4d4b8b4603/html5/thumbnails/56.jpg)
A Patient Journey Through Statin Intolerance
![Page 57: Current Controversies in Dyslipidemia Management:](https://reader036.vdocuments.net/reader036/viewer/2022081515/58ecde6f1a28ab4d4b8b4603/html5/thumbnails/57.jpg)
![Page 58: Current Controversies in Dyslipidemia Management:](https://reader036.vdocuments.net/reader036/viewer/2022081515/58ecde6f1a28ab4d4b8b4603/html5/thumbnails/58.jpg)
![Page 59: Current Controversies in Dyslipidemia Management:](https://reader036.vdocuments.net/reader036/viewer/2022081515/58ecde6f1a28ab4d4b8b4603/html5/thumbnails/59.jpg)